The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) in Europe.
Guy Heinrich Maria Jerusalem
Consultant or Advisory Role - Novartis
Patrick Neven
No relevant relationships to disclose
Nina Marinsek
Consultant or Advisory Role - Novartis
Jie Zhang
Employment or Leadership Position - Novartis
Ravi Degun
Consultant or Advisory Role - Novartis
Giancarlo Benelli
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Stephen Saletan
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Fabrice Andre
Consultant or Advisory Role - AstraZeneca; Novartis; Roche; Sanofi
Honoraria - AstraZeneca; Novartis; Roche; Sanofi